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BCL6 is a transcriptional repressor that is overexpressed in diffuse large B-cell
lymphoma and follicular lymphoma. The N-terminal POZ domain of BCL6
interacts with transcriptional corepressors and targeting these associations is a
promising therapeutic strategy. Previous structural studies of the BCL6 POZ
domain have used a mutant form because of the low solubility of the wild-type
recombinant protein. A method for the puriﬁcation and crystallization of the
wild-type BCL6 POZ domain is described and the crystal structure to 2.1 A˚
resolution is reported. This will be relevant for the design of therapeutics that
target BCL6 POZ-domain interaction interfaces.
1. Introduction
BCL6 (B-cell lymphoma 6) is a zinc-ﬁnger transcription factor that
regulates B-cell development (Chang et al., 1996). It is expressed at
high levels in germinal centre B cells (Cattoretti et al., 1995), where
somatic hypermutation and class-switch recombination of the
immunoglobulin genes lead to the production of high-afﬁnity anti-
bodies. In this setting, BCL6 represses the transcription of genes that
control cell-cycle arrest, apoptosis, differentiation and the DNA-
damage response, thereby enabling the rapid proliferation of germ-
inal centre B cells that are undergoing DNA deletions and mutations
(Baron et al., 1997; Phan & Dalla-Favera, 2004; Parekh et al., 2007;
Ranuncolo et al., 2007). The expression of BCL6 is crucially down-
regulated at the end of the germinal centre (GC) reaction, thus
allowing the differentiation of B cells into plasma cells and memory B
cells. Chromosome translocations and mutations affecting the pro-
moter of the BCL6 gene are observed in diffuse large B-cell
lymphoma (DLBCL) and follicular lymphoma (FL) (Baron et al.,
1993; Kerckaert et al., 1993; Ye et al., 1993, 1995); the resulting over-
expression of BCL6 blocks the differentiation and apoptosis of B
cells, leading to their retention at the proliferative GC stage.
Targeting BCL6 function is a promising therapeutic strategy for some
DLBCL patients (Chattopadhyay et al., 2006; Parekh et al., 2008; Polo
et al., 2004).
The N-terminal POZ/BTB (poxvirus and zinc ﬁnger/bric-a`-brac,
tramtrack and broad complex) domain of BCL6 mediates many of its
transcriptional properties. The POZ domain is a conserved protein–
protein interaction motif that is found in approximately 40 zinc-ﬁnger
transcription factors (POZ-ZF factors; reviewed in Stogios et al.,
2005). Most POZ-ZF factors have roles in development and many are
implicated as oncogenes or tumour suppressors in human cancer
(reviewed in Kelly & Daniel, 2006); for example, PLZF (promyelo-
cytic leukaemia zinc ﬁnger; Chen et al., 1993), BCL6 and LRF
(leukaemia/lymphoma-related factor; Maeda et al., 2005) are in-
volved in speciﬁc types of leukaemia and lymphoma. POZ domains
direct the oligomerization of POZ-ZF factors and also mediate the
recruitment of transcriptional coregulators and other non-POZ
partners (Huynh & Bardwell, 1998). POZ-ZF factors are thought to
function as biological dimers and crystal structures of the PLZF
(Ahmad et al., 1998; Li et al., 1999), BCL6 (Ahmad et al., 2003; Ghetu
et al., 2008) and LRF (Schubot et al., 2006; Stogios et al., 2007) POZ
domains revealed domain-swapped homodimers with a conserved
# 2008 International Union of Crystallography
All rights reserved
electronic reprint
BTB fold. Higher order oligomers and heteromeric interactions of
POZ-ZF factors are also biologically important and some of the
activities of BCL6 are mediated by a POZ–POZ interaction between
BCL6 and the POZ-ZF factor Miz-1 (Phan et al., 2005). The stoi-
chiometries of heteromeric POZ-domain complexes are unknown.
The recent crystal structure of the Miz-1 POZ domain (Stead et al.,
2007) revealed a tetrameric organization in which two POZ dimers
interact via the solvent-exposed -sheets located along one surface.
This -sheet interface mediates the tetramerization of the Miz-1 POZ
domain in solution and may be a candidate for mediating the higher
order association and hetero-oligomerization of other POZ-ZF
factors.
The BCL6 POZ domain recruits the transcriptional corepressors
BCoR (BCL6-interacting corepressor), SMRT (silencing mediator
for retinoid and thyroid hormone receptors) and NCoR (nuclear
receptor corepressor) in a mutually exclusive manner by recognition
of the 17-residue BBD (BTB-binding domain) region of the co-
repressors. No BBD motif exists at the sequence level; although the
SMRT and NCoR BBD sequences are highly conserved, the BCoR
BBD shares no similarity with either. Crystal structures of the BCL6
POZ domain in complex with SMRTor BCoR BBD peptides showed
that these corepressors use very different determinants for recogni-
tion of the same binding surface of the BTB dimer (Ahmad et al.,
2003; Ghetu et al., 2008). Peptides that mimic either the SMRT or
BCoR BBDs led to the killing of BCL6-positive DLBCL tumour
cells, indicating potential therapeutic applications.
All reported crystal structures of the BCL6 POZ domain represent
a mutant protein in which three surface cysteine residues were altered
in order to enhance solubility and to aid the puriﬁcation of recom-
binant protein. Since these mutations are located in regions that may
be involved in either POZ-domain oligomerization or the recruit-
ment of other factors, it is advantageous to additionally determine the
structure of the wild-type protein. We present a method for the
puriﬁcation and crystallization of the wild-type BCL6 POZ domain
and report the crystal structure to 2.1 A˚ resolution.
2. Materials and methods
2.1. Cloning
A DNA fragment encoding the BCL6 POZ domain (BCL6 resi-
dues 5–129) was ampliﬁed from a human placental cDNA library and
inserted into pGEX-6P-1 (GE Healthcare). The resulting plasmid
encoded a fusion protein containing an N-terminal glutathione
S-transferase (GST) tag and a PreScission protease cleavage site.
2.2. Protein expression and purification
Protocols for expression of the recombinant wild-type BCL6 POZ
domain were optimized to speciﬁcally increase the proportion of
protein obtained in the soluble fraction. GST-fusion proteins were
expressed in Escherichia coli Rosetta (DE3) pLysS (Novagen).
Bacteria were cultured at 310 K to an OD600 nm of 0.6 in 2TY broth
supplemented with 0.3% ethanol (Steczko et al., 1991). Cells were
cooled rapidly on ice and recombinant protein expression was
induced with 0.1 mM IPTG at 289 K for 16 h. Bacterial pellets were
resuspended in PBS, 0.1% Triton X-100, 5 mMDTT pH 7.5; inclusion
of 5 mM DTT in all buffers was essential for recombinant protein
stability and subsequent puriﬁcation. Cells were lysed by sonication
and fusion proteins were bound to glutathione-Sepharose 4B (GE
Healthcare). The GST tag was subsequently removed by cleavage
with PreScission protease in 20 mM Tris–HCl, 75 mM NaCl, 5 mM
DTT pH 7.5. The BCL6 POZ domain was further puriﬁed by anion-
exchange chromatography on Resource Q in 10 mM Tris–HCl,
50 mM NaCl, 5 mM DTT pH 8.5 and eluted with a 50–300 mM NaCl
gradient. This was followed by size-exclusion chromatography on a
Superdex 75 HiLoad 26/60 column (GE Healthcare). The protein was
eluted in 20 mM Tris–HCl, 250 mM NaCl, 5 mM DTT, 5% glycerol
pH 8.5 and concentrated to 4.5 mg ml1 using Amicon centrifugal
concentrators (Millipore).
2.3. Crystallization
Crystals of the BCL6 POZ domain were grown at 291 K using
sitting-drop vapour diffusion by mixing 2 ml protein solution
(4.5 mg ml1) with 3 ml reservoir solution (2.5M NaNO3, 100 mM
sodium acetate pH 4.5, 40 mM spermidine). Large hexagonal crystals
were typically obtained after 48 h. Crystals were mounted in a nylon
CryoLoop (Hampton Research) and transferred into mother liquor
supplemented with 17.5% glycerol for 30 s before being ﬂash-frozen
in liquid nitrogen.
2.4. Data collection, structure determination and refinement
X-ray diffraction data were collected under a nitrogen-gas stream
at 100 K at the Diamond Synchrotron Light Source (Didcot, UK),
beamline I04. Data reduction was performed using iMOSFLM and
SCALA (Collaborative Computational Project, Number 4, 1994;
Leslie, 1992). The cumulative intensity distribution calculated within
TRUNCATE (French & Wilson, 1978) suggested the data were
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Table 1
Data-collection and processing statistics.
Values in parentheses are for the highest resolution shell.
Crystal parameters
Space group P32
Unit-cell parameters (A˚, ) a = 59.21, b = 59.21, c = 158.97,
 = 90,  = 90,  = 120
Data collection
Resolution (A˚) 36.86–2.10 (2.21–2.10)
Wavelength (A˚) 0.972
Rmerge† (%) 6.8 (15.7)
Rp.i.m.‡ (%) 4.0 (9.2)
hI/(I)i 16.3 (4.6)
No. of unique reﬂections 36195
Multiplicity 3.8 (3.9)
Completeness (%) 99.4 (100)
Twinning
Twin fraction
Twin operator h, k, l 0.539
Twin operator h, h + k, l 0.461
Reﬁnement
Resolution (A˚) 2.1
R§ (%) 21.9
Rfree} (%) 25.9
R.m.s.d. stereochemistry††
Bond lengths (A˚) 0.011
Bond angles () 1.294
No. of protein atoms 5827
No. of water molecules 256
Average B factor (A˚2) 33.169
Ramachandran analysis‡‡ (%)
Favoured 97.3
Allowed 100.0
Disallowed 0
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the integrated
intensity of a given reﬂection and hI(hkl)i is the mean intensity of multiple corresponding
symmetry-related reﬂections. ‡ Rpim =
P
hkl ½1=ðN  1Þ1=2
P
i jIiðhklÞ  hIðhklÞij=P
hkl
P
i IiðhklÞ, where Ii(hkl) is the integrated intensity of a given reﬂection, hI(hkl)i
is the mean intensity of multiple corresponding symmetry-related reﬂections and N is the
multiplicity of a given reﬂection. § R =
P
hkl

jFojhkl  jFcjhkl

=
P
hkl jFojhkl , where Fo
and Fc are the observed and calculated structure factors, respectively. } Rfree is R
calculated using 5% random data excluded from the reﬁnement. †† R.m.s.d.
stereochemistry is the deviation from ideal values. ‡‡ Ramachandran analysis was
carried out using MolProbity (Davis et al., 2007).
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twinned. This was conﬁrmed by the generation of Britton plots
(Britton, 1972) within the program DETWIN (Rees, 1980), which
revealed a twin fraction of 46%. Matthews analysis (Kantardjieff &
Rupp, 2003) suggested the presence of three BCL6 dimers within the
asymmetric unit and native Patterson maps calculated using
detwinned data displayed peaks that suggested that the three dimers
were related by translational NCS. Initial phase estimates were
generated using the molecular-replacement program AMoRe
(Navaza, 2001), using a mutant BCL6 POZ domain (Ahmad et al.,
2003; PDB code 1r28) as the search model. The asymmetric unit
contained three POZ-domain dimers related by purely translational
NCS that were positioned sequentially. The ﬁnal model was built by
iterative model building in Coot (Emsley & Cowtan, 2004) and
twinned reﬁnement using REFMAC v.5.5 (Murshudov et al., 1997).
Stereochemistry was analysed with the PROCHECK (Laskowski et
al., 1993) and MolProbity (Davis et al., 2007) programs. Structure
superpositions were calculated using the SUPERPOSE server (Maiti
et al., 2004) and images of protein structures were prepared using
PyMOL (DeLano, 2002).
3. Results and discussion
The wild-type human BCL6 POZ domain (BCL6 residues 5–129) was
expressed in E. coli, puriﬁed and crystallized. The crystals were
merohedrally twinned and the asymmetric unit contained three POZ-
domain dimers that were related by translational NCS. The structure
was solved by molecular replacement and reﬁned to R = 21.9%,
Rfree = 25.9% at 2.1 A˚ resolution (Table 1, Fig. 1).
The organization of the wild-type BCL6 POZ domain is the same
as previously reported POZ-domain dimers, with each subunit
containing a core of -helices that is ﬂanked at the top and bottom by
-sheets (described according to the orientation depicted in Fig. 1).
The dimerization interface comprises a central region consisting of
-helices, together with two two-stranded -sheets (1–50) that lie at
the bottom of the molecule. The N-termini of the subunits are
exchanged to yield a domain-swapped dimer in which each -sheet of
the dimerization interface contains a strand derived from each
subunit. Compared with the wild-type BCL6 POZ domain, the
r.m.s.d. values of C-atom positions for the reported mutant BCL6
POZ domains are 1.5 A˚ (PDB code 1r2b), 0.97 A˚ (1r28), 1.10 A˚
(1r29) (Ahmad et al., 2003) and 1.12 A˚ (3bim; Ghetu et al., 2008); in
comparison, similar superposition of 1r29 with other BCL6 POZ-
domain structures yields r.m.s.d. values of 1.08 A˚ (1r2b), 0.92 A˚
(1r28) and 1.13 A˚ (3bim).
Previously reported BCL6 POZ-domain structures represent
proteins that contain mutations of three cysteine residues (C8Q,
C67R and C84N) to enhance the solubility and the puriﬁcation of the
recombinant protein. These cysteine residues are not conserved
between POZ domains of different POZ-ZF factors. Cys8 is located
in the N-terminal 1 strand that forms part of the POZ-domain
dimerization interface, Cys67 is in the unstructured loop between 3
and 4 and Cys84 is in 4 on the outside of the dimer.
The side chains of Cys8, Cys67 and Cys84 in the wild-type BCL6
POZ domain are solvent-exposed (Figs. 1 and 2); the 1 Cys8 and 4
Cys84 side chains of opposite subunits of the domain-swapped dimer
point outwards from the same face of the molecule. The 1–50 sheets
of the reported mutant (C8Q,C67R,C84N) BCL6 POZ domains form
approximately 35% of the dimerization interface; there is no sub-
stantial main-chain deviation between the wild-type and mutant
structures in this region (Fig. 2). The 1–50 sheet also plays a crucial
role in the recruitment of the corepressors SMRT and BCoR, which
interact with the lateral groove that runs along the bottom of the
dimer and extends into the dimerization interface (Ahmad et al.,
2003; Ghetu et al., 2008). Two molecules of corepressor interact with
the POZ-domain dimer and each contributes a lower third strand to
protein structure communications
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Figure 2
Comparison of wild-type and mutant BCL6 POZ-domain structures. The residues surrounding Cys8, Cys67 and Cys84 are shown in a stick representation. The wild-type
BCL6 POZ domain (ochre) is superposed with the corresponding region from the reported mutant (green; C8Q,C67R,C84N; PDB code 1r28; Ahmad et al., 2003). Cysteine S
atoms are highlighted in magenta. A 2|Fo|  |Fc| electron-density map corresponding to the wild-type BCL6 POZ domain data, contoured to 1.5, is shown in blue.
Figure 1
Ribbon representation of the wild-type BCL6 POZ-domain dimer. Subunits A and
B are shown in red and blue, respectively, and the secondary-structure elements of
the A chain and of the 1–50 interface are labelled (positions of the B chain are
indicated by primes). Residues Cys8, Cys67 and Cys84 were mutated in previously
reported BCL6 POZ-domain structures and are indicated by asterisks. The lateral
groove has been shown to mediate the recruitment of corepressors SMRT and
BCoR (Ahmad et al., 2003; Ghetu et al., 2008).
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one of the 1–50 -sheets. The structure of the mutant BCL6 POZ
domain in complex with either SMRTor BCoR revealed corepressor
contacts involving both the main chain and side chain of the mutated
residue 8 (Ahmad et al., 2003; Ghetu et al., 2008); the effect of Cys8
mutation on corepressor interactions remains to be determined.
Cys67 is located in the loop between 3 and 4 at the top of the
BCL6 POZ-domain dimer (Figs. 1 and 2). This region is highly ﬂex-
ible and the corresponding loop of the Miz-1 POZ domain undergoes
signiﬁcant rearrangement when Miz-1 POZ dimers associate into
tetramers (Stead et al., 2007). Tetramerization of the Miz-1 POZ
domain is mediated via the interaction of dimers at the exposed
3–2–4 sheets located at the top of each subunit; this interaction
results in the displacement of an outer 4 strand from one subunit of
each constituent dimer, with the 3–4 loop being repositioned to
reside adjacent to the -sheet tetramerization interface. Although it
is not currently known whether the BCL6 POZ-domain dimer uses a
similar interface for higher order homo- or hetero-oligomerization, it
will now be relevant to evaluate the effect of the C67R mutation on
POZ-domain interactions involving this region.
The crystal structure of the wild-type BCL6 POZ domain conﬁrms
previously reported structures of a mutant protein and shows that the
C8Q, C67R and C84N mutations have no effect on the overall
backbone conformation. It will now be pertinent to study the inter-
action of the wild-type POZ domain both with transcriptional co-
regulators and with other POZ partners. Knowledge of the structure
of the wild-type BCL6 POZ domain will have direct relevance for the
design of therapeutics that target its interactions in B-cell lymphoma.
This work was funded by Yorkshire Cancer Research. We thank
staff at the Diamond Synchrotron Light Source (Didcot, UK) and Dr
Arwen Pearson (University of Leeds) for assistance during X-ray
data collection.
References
Ahmad, K. F., Engel, C. K. & Prive´, G. G. (1998). Proc. Natl Acad. Sci. USA,
95, 12123–12128.
Ahmad, K. F., Melnick, A., Lax, S., Bouchard, D., Liu, J., Kiang, C. L., Mayer,
S., Takahashi, S., Licht, J. D. & Prive´, G. G. (2003).Mol. Cell, 12, 1551–1564.
Baron, B. W., Desai, M., Baber, L. J., Paras, L., Zhang, Q., Sadhu, A., Duguay,
S., Nucifora, G., McKeithan, T. W. & Zeleznik-Le, N. (1997). Genes
Chromosomes Cancer, 19, 14–21.
Baron, B. W., Nucifora, G., McCabe, N., Espinosa, R. III, Le Beau, M. M. &
McKeithan, T. W. (1993). Proc. Natl Acad. Sci. USA, 90, 5262–5266.
Britton, D. (1972). Acta Cryst. A28, 296–297.
Cattoretti, G., Chang, C. C., Cechova, K., Zhang, J., Ye, B. H., Falini, B., Louie,
D. C., Ofﬁt, K., Chaganti, R. S. & Dalla-Favera, R. (1995). Blood, 86, 45–53.
Chang, C. C., Ye, B. H., Chaganti, R. S. & Dalla-Favera, R. (1996). Proc. Natl
Acad. Sci. USA, 93, 6947–6952.
Chattopadhyay, A., Tate, S. A., Beswick, R. W., Wagner, S. D. & Ko Ferrigno, P.
(2006). Oncogene, 25, 2223–2233.
Chen, S. J., Zelent, A., Tong, J. H., Yu, H. Q., Wang, Z. Y., Derre, J., Berger, R.,
Waxman, S. & Chen, Z. (1993). J. Clin. Invest. 91, 2260–2267.
Collaborative Computational Project, Number 4 (1994). Acta Cryst. D50,
760–763.
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X.,
Murray, L. W., Arendall, W. B. III, Snoeyink, J., Richardson, J. S. &
Richardson, D. C. (2007). Nucleic Acids Res. 35, W375–W383.
DeLano, W. L. (2002). The PyMOL Molecular Graphics System. http://
www.pymol.org.
Emsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132.
French, S. & Wilson, K. (1978). Acta Cryst. A34, 517–525.
Ghetu, A. F., Corcoran, C. M., Cerchietti, L., Bardwell, V. J., Melnick, A. &
Prive´, G. G. (2008). Mol. Cell, 29, 384–391.
Huynh, K. D. & Bardwell, V. J. (1998). Oncogene, 17, 2473–2484.
Kantardjieff, K. A. & Rupp, B. (2003). Protein Sci. 12, 1865–1871.
Kelly, K. F. & Daniel, J. M. (2006). Trends Cell Biol. 16, 578–587.
Kerckaert, J. P., Deweindt, C., Tilly, H., Quief, S., Lecocq, G. & Bastard, C.
(1993). Nature Genet. 5, 66–70.
Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. (1993). J.
Appl. Cryst. 26, 283–291.
Leslie, A. G.W. (1992). Jnt CCP4/ESF–EACBMNewsl. Protein Crystallogr. 26.
Li, X., Peng, H., Schultz, D. C., Lopez-Guisa, J. M., Rauscher, F. J. III &
Marmorstein, R. (1999). Cancer Res. 59, 5275–5282.
Maeda, T., Hobbs, R. M. & Pandolﬁ, P. P. (2005). Cancer Res. 65, 8575–8578.
Maiti, R., Van Domselaar, G. H., Zhang, H. & Wishart, D. S. (2004). Nucleic
Acids Res. 32, W590–W594.
Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997). Acta Cryst. D53,
240–255.
Navaza, J. (2001). Acta Cryst. D57, 1367–1372.
Parekh, S., Polo, J. M., Shaknovich, R., Juszczynski, P., Lev, P., Ranuncolo,
S. M., Yin, Y., Klein, U., Cattoretti, G., Dalla Favera, R., Shipp, M. A. &
Melnick, A. (2007). Blood, 110, 2067–2074.
Parekh, S., Prive´, G. & Melnick, A. (2008). Leuk. Lymphoma, 49, 874–882.
Phan, R. T. & Dalla-Favera, R. (2004). Nature (London), 432, 635–639.
Phan, R. T., Saito, M., Basso, K., Niu, H. & Dalla-Favera, R. (2005). Nature
Immunol. 6, 1054–1060.
Polo, J. M., Dell’Oso, T., Ranuncolo, S. M., Cerchietti, L., Beck, D., Da Silva,
G. F., Prive´, G. G., Licht, J. D. & Melnick, A. (2004). Nature Med. 10, 1329–
1335.
Ranuncolo, S. M., Polo, J. M., Dierov, J., Singer, M., Kuo, T., Greally, J., Green,
R., Carroll, M. & Melnick, A. (2007). Nature Immunol. 8, 705–714.
Rees, D. C. (1980). Acta Cryst. A36, 578–581.
Schubot, F. D., Tropea, J. E. & Waugh, D. S. (2006). Biochem. Biophys. Res.
Commun. 351, 1–6.
Stead, M. A., Trinh, C. H., Garnett, J. A., Carr, S. B., Baron, A. J., Edwards,
T. A. & Wright, S. C. (2007). J. Mol. Biol. 373, 820–826.
Steczko, J., Donoho, G. A., Dixon, J. E., Sugimoto, T. & Axelrod, B. (1991).
Protein Expr. Purif. 2, 221–227.
Stogios, P. J., Chen, L. & Prive´, G. G. (2007). Protein Sci. 16, 336–342.
Stogios, P. J., Downs, G. S., Jauhal, J. J., Nandra, S. K. & Prive´, G. G. (2005).
Genome Biol. 6, R82.
Ye, B. H., Chaganti, S., Chang, C. C., Niu, H., Corradini, P., Chaganti, R. S. &
Dalla-Favera, R. (1995). EMBO J. 14, 6209–6217.
Ye, B. H., Lista, F., Lo Coco, F., Knowles, D. M., Ofﬁt, K., Chaganti, R. S. &
Dalla-Favera, R. (1993). Science, 262, 747–750.
protein structure communications
1104 Stead et al.  BCL6 POZ domain Acta Cryst. (2008). F64, 1101–1104
electronic reprint
